Commentary
Medicare's GLP-1 Bridge Program: My Full Comments to Moneywise
A news article has room for a sentence or two. Below are the complete answers I gave to Moneywise, unedited.
On what 200,000 prescriptions in under 60 days tells us
Two hundred thousand prescriptions this quickly tells you there was significant pent-up demand. When a medication suddenly becomes $50 and patients rush to get it, the price was clearly acting as a gatekeeper. The clinical demand didn't appear overnight; the affordability did.
On the eligibility criteria
For a demonstration program, tighter eligibility makes economic sense. But medically, there is a contradiction in waiting for some patients with obesity to develop additional disease before making treatment affordable. Prevention works best before the complications happen.
On how the program's value should be measured
Taxpayers shouldn't judge this program by pounds lost. The benefits of this program should be viewed from a holistic lens. Look at hospitalizations, cardiovascular events, progression to diabetes, mobility, medication burden, and total healthcare spending. A treatment does not necessarily have to save Medicare money dollar-for-dollar to be valuable.
On what happens when the program ends
The affordability cliff may be the biggest problem with the program. These medications treat a chronic disease; they aren't an 18-month cure. Starting someone at $50 a month and then taking affordable access away creates a very predictable discontinuation problem. A temporary program needs an exit strategy before patients enter it.
On what would justify broader Medicare coverage
If the data show meaningful reductions in obesity-related disease at a reasonable cost, the argument for broader Medicare coverage becomes much stronger. Congress doesn't need evidence that GLP-1s magically pay for themselves. It needs evidence that the health benefit justifies the cost, along with sustainable pricing that makes coverage possible at Medicare scale.
Related coverage
Moneywise (original, August 31, 2026): 200,000 Medicare users sprint to CVS and Walgreens to snatch up $50 obesity drugs, millions more are still missing out, by Brian O'Connell.
Yahoo Finance: syndicated coverage.
AOL: syndicated coverage.
Yahoo Finance Canada: syndicated coverage.
World Journal (世界日報) (independent Chinese-language reporting, September 1 and 2, 2026): 20萬紅藍卡持有人 透過CVS、Walgreens以50元取得減重藥 and a second report, both naming Bidwell Cranage and Bidwell Health.
Moneywise is the original publication. Yahoo Finance, AOL and Yahoo Finance Canada carry the syndicated version. World Journal reported the story separately in its own newsroom.